myhematology.com
Jan 2, 2025, 16:48
Ahmed Kotb: FLT3 Inhibitors choice in AML
Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company (KFSHI), shared a post on X:
“FLT3 Inhibitors choice in AML:
Midostaurin vs. Quizartinib
Midostaurin:
Targets FLT3-ITD & FLT3-TKD
QTc <500ms
Favored in males
maintenance post-chemotherapy
Quizartinib:
Targets FLT3-ITD only
QTc <450 ms
Favored in females, WBC ≥40, NPM1-mutated
maintenance post-alloTx.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41
Sep 2, 2025, 16:27
Sep 2, 2025, 16:24
Sep 2, 2025, 16:18
Sep 2, 2025, 15:56